{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T02:12:23Z","timestamp":1722651143541},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,9]]},"DOI":"10.7759\/cureus.13787","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T20:30:48Z","timestamp":1615321848000},"source":"Crossref","is-referenced-by-count":2,"title":["Statin-Induced Necrotizing Autoimmune Myositis: Diagnosis and Management"],"prefix":"10.7759","author":[{"given":"David","family":"Cha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basanti","family":"Mukerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaskar","family":"Mukerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine L","year":"2010","unstructured":"Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune mediated necrotizing myopathy. Arthritis Rheum. 2010, 62:2757-2766. 10.1002\/art.27572","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"2011","author":"Abd TT","unstructured":"Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011:373-387. 10.1517\/14740338.2011.540568","journal-title":"Expert Opin Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen AL","year":"2016","unstructured":"Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016, 374:664-669. 10.1056\/NEJMra1515161","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e328364e9d9","article-title":"Acquired necrotizing myopathies","volume":"26","author":"Allenbach Y","year":"2013","unstructured":"Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol. 2013, 26:554-560. 10.1097\/WCO.0b013e328364e9d9","journal-title":"Curr Opin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Stain-associated side effects","volume":"67","author":"Thompson PD","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Stain-associated side effects. J AM Coll Cardiol. 2016, 67:2395-2410. 10.1016\/j.jacc.2016.02.071","journal-title":"J AM Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014, 8:58-71. 10.1016\/j.jacl.2014.03.004","journal-title":"J Clin Lipidol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.004249","article-title":"Prevalence and management of symptoms associated with statin therapy in community practice: Insights from the PALM (Patient and Provider Assessment of Lipid Management) Registry","volume":"11","author":"Navar AM","year":"2018","unstructured":"Navar AM, Peterson ED, Li S, et al.. Prevalence and management of symptoms associated with statin therapy in community practice: Insights from the PALM (Patient and Provider Assessment of Lipid Management) Registry. Circ Cardiovasc Qual Outcomes. 2018, 11:004249. 10.1161\/CIRCOUTCOMES.117.004249","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood FA","year":"2020","unstructured":"Wood FA, Howard JP, Finegold JA, et al.. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020, 383:2182-2184. 10.1056\/NEJMc2031173","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law M","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am H Cardiol. 2006, 97:52-60. 10.1016\/j.amjcard.2005.12.010","journal-title":"Am H Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang C","year":"2011","unstructured":"Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011, 23:612-619. 10.1097\/BOR.0b013e32834b324b","journal-title":"Curr Opin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000106","article-title":"Necrotizing myopathies: beyond statins","volume":"26","author":"Mammen AL","year":"2014","unstructured":"Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheumatol. 2014, 26:679-683. 10.1097\/BOR.0000000000000106","journal-title":"Curr Opin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel P","year":"2018","unstructured":"Mohassel P, Mammen AL. Anti-HMGCR myopathy. J Neuromuscul Dis. 2018, 5:11-20. 10.3233\/JND-170282","journal-title":"J Neuromuscul Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen AL","year":"2012","unstructured":"Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, Gaudet D. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken). 2012, 64:269-272. 10.1002\/acr.20662","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat P","year":"2015","unstructured":"Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015, 17:72. 10.1007\/s11926-015-0548-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle disease","volume":"373","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle disease. N Engl J Med. 2015, 373:393-394. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung T","year":"2015","unstructured":"Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve. 2015, 52:189-195. 10.1002\/mus.24642","journal-title":"Muscle Nerve"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya M","year":"2016","unstructured":"Kadoya M, Hida A, Hashimoto Maeda M, et al.. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016, 3:290. 10.1212\/NXI.0000000000000290","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan S","year":"2015","unstructured":"Ramanathan S, Langguth D, Hardy TA, et al.. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015, 2:96. 10.1212\/NXI.0000000000000096","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53504-statin-induced-necrotizing-autoimmune-myositis-diagnosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:29Z","timestamp":1707507029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53504-statin-induced-necrotizing-autoimmune-myositis-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.13787","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}